Moneycontrol PRO
Open App
you are here: HomeNewsBusinessIPO

Global Health, Veeda Clinical receive Sebi approval to launch IPOs

Veeda Clinical Research's Rs 831-crore IPO consists of an issuance of fresh equity shares worth up to Rs 331.60 crore and an OFS of Rs 500 crore by promoters and existing shareholders.

December 27, 2021 / 08:43 PM IST
Global Health IPO, Veeda Clinical IPO receive Sebi approval

Global Health IPO, Veeda Clinical IPO receive Sebi approval

Global Health, which operates and manages hospitals under the Medanta brand, and clinical research organisation Veeda Clinical Research has received markets regulator Sebi's go-ahead to raise funds through an initial public offering (IPO).

These companies, which filed their preliminary IPO with Sebi in September, obtained its observations on December 21, an update with the regulator showed on Monday.

In Sebi parlance, the issuance of observations letter implies its go-ahead for the IPO.

Going by the draft papers, Global Health's IPO consists of a fresh issue of equity shares aggregating to Rs 500 crore, and an offer for sale of up to 4.84 crore equity shares.

Click Here To Read All IPO Related News

Close

As part of the offer-for-sale (OFS), Anant Investments, an affiliate of private equity major Carlyle Group, will sell up to 4.33 crore equity shares and Global Health co-founder Sunil Sachdeva (jointly with Suman Sachdeva) will offload up to 51 lakh equity shares.

The proceeds from the fresh issue will be used to pay debt and general corporate purposes.

Co-founded by Naresh Trehan, a renowned cardiovascular and cardiothoracic surgeon, Global Health is a leading private multi-speciality tertiary care providers in the north and east regions of India.

Also readSupriya Lifescience trades at strong GMP. Will it see a stellar listing on December 28?

Veeda Clinical Research's Rs 831-crore IPO consists of an issuance of fresh equity shares worth up to Rs 331.60 crore and an OFS of Rs 500 crore by promoters and existing shareholders.

Investors participating in OFS include CX Alternative Investment Fund aggregating up to Rs 8.08 crore, Rs 90.19 crore by Arabelle Financial Services, Rs 259.77 crore by Bondway Investment Inc., Rs 0.04 crore by Stevey International Corporation and Rs 141.93 crore by Basil Private Limited.

The company intends to utilise net proceeds from the fresh issue for repayment of the debt, funding capital expenditure, funding further acquisition of subsidiary Bioneeds India, funding working capital requirements besides general corporate purposes.
PTI
first published: Dec 27, 2021 08:43 pm
Sections
ISO 27001 - BSI Assurance Mark